Drug intelligence / Profile preview

CTA-006

Development stage: Preclinical
Lead developer: CytoArm Biotechnology
Modality: Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CTA-006 is an experimental cell therapy being developed by CytoArm, in collaboration with SL-LINK, for the treatment of recurrent and refractory solid tumors. It utilizes the proprietary Armed-T™ platform, which involves engineering T cells to improve their therapeutic efficacy against malignancies. As of the current pipeline information, the specific biological target and the exact stage of clinical development have not been publicly disclosed, though it remains an active part of CytoArm's oncology portfolio targeting solid tumors.

Other names: Armed-T cell therapy

Beyond the preview

Go deeper on CTA-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTA-006.

Explore the full profile